89bio

📍 San Francisco, United States🗓 Founded 2018👥 139 employees💰 Last funded Sep 2025
Biotechnology Research🌐 89bio.com
Website LinkedIn
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Our culture is best described by our values: • Always putting the patient first • Operating with the highest integrity and ethical standards at all times • Being authentic in all our transactions • Acting as a team – collaborating, respecting and caring for one another • Being entrepreneurial and passionate in our tasks • Being scientific and rational in our thought process and decision-making
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Italy
1
Frequently asked questions
Who invested in 89bio?
89bio has 1 investors on record on gritt.io and 1 late-stage investors.
When did 89bio last raise funding?
The most recent investment in 89bio recorded on gritt.io was in September 2025.
When was 89bio founded?
89bio was founded in 2018.
What industry is 89bio in?
89bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is 89bio based?
89bio is headquartered in San Francisco, United States.